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Measurement of serum 17-hydroxyprogesterone by LC-MS/MS is associated with a 
lower probability of false positive results compared to immunoassay as a screening for 
21-hydroxylase-deficient nonclassic adrenal hyperplasia in woman with 
hyperandrogenism. 
Short title: 17-hydroxyprogesterone measured by LC-MS/MS  
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Abstract:  
Basal serum 17OHP measurement remains the first screening step for NCCAH and the 
accuracy of the test is of high value.  
The aim of this study was to compare the accuracy of immunoassays to LC-MS/MS in the 
assessment of serum 17OHP and androgens concentration in woman with hyperandrogenism 
and controls.  
17OHP, total testosterone, androstendione and DHEAS were measured in 39 women with 
clinically and/or biochemically evident hyperandrogenism and in 29 age-matched controls 
without clinical hyperandrogenism. 17OHP and androgens were measured by immunoassays 
and by LC-MS/MS.  
In patients group 17OHP level measured by immunoassays was significantly higher compared 
to LC-MS/MS (ELISA NovaTec
®
 vs LC-MS/MS P<0.0001, ELISA DRG
®
 vs LC-MS/MS 
P<0.0001) as well as in control group (ELISA DRG
®
 vs LC-MS/MS P<0.0001). Additional, 
unnecessary diagnostic procedures explaining elevated 17OHP level were undertaken in 85% 
of patients when NovaTec
®
 test was used, in 50% when ELISA DRG
®
 and in none when  LC-
MS/MS method was applied. Total testosterone, androstendione and DHEAS concentrations 
in the patients and the controls assessed by the immunoassays were also significantly higher 
compared to LC-MS/MS.  
LC-MS/MS is more reliable diagnostic tool in the measurement of serum 17OHP and 
androgens concentrations compared to immunoassays in woman with hyperandrogenism. 
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Introduction  
Hyperandrogenism represents one of the most common endocrinopathy affecting about 10 % 
of woman of reproductive age and provides a negative impact on patients quality of life 
[1,2,3]. Nonclassic congenital adrenal hyperplasia (NCCAH) is specific, identifiable 
androgenic disorder, which needs to be confirmed by 17-hydroxyprogesterone (17OHP) 
measurement [4,5,6,7,8,9]. It is essential however to use reliable assays for quantifying 
17OHP. The development of automated platforms gave direct assays the advantages of being 
convenient and relatively cheap, but on the other hand the assays occurred frequently to 
overestimate the measurements due to the lack of specificity of the antibodies. False positive 
17OHP results may lead to patients distress and unnecessary, costly procedures. Therefore, 
there is a need of high validity methods in screening 17OHP measurements in order to select a 
group of patients for further diagnostic approach. In the past decade liquid chromatography 
coupled with mass spectrometry (LC-MS/MS) has revolutionized measurement of steroid 
hormones in various body fluids improving sensitivity, specificity and enabling automation of 
measurement [10,11].  
The aim of the study was to compare the accuracy of widely used immunoassays with LC-
MS/MS method in the assessment of serum 17OHP and androgens concentration in woman 
with hyperandrogenism and controls.  
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Material and Methods:  
Subjects  
39 women (18-45 year old, mean age 25.9) with clinically and/or biochemically evident 
hyperandrogenism were included into the study. All patients were hospitalized in the 
Department of Internal Medicine and Endocrinology, Medical University of Warsaw between 
June 2012 and February 2014.  
The control group consisted of 29 healthy woman aged 19-45years (mean age 27.9) with 
regular menses, without clinical hyperandrogenism (acne and/or androgenic alopecia and/or 
hirsutism and/or virilization). Exclusion criteria for both groups were as follows: age < 18 
years or > 45 years, pregnancy, recent history (until 3 months) of hormonal contraceptive or 
hormonal replacement therapy use, thyroid dysfunction, hyperprolactinemia.  
All the patients undergone clinical and hormonal assessment as well as pelvic and adrenal 
ultrasound (US). In case of adrenal tumor suspicion on US,  computed tomography of adrenal 
glands was performed.  
Clinical evaluation of the patients was based on anthropometric measurements (weight, 
height), body mass index (BMI), age, the data of menstruation regularity, presence of 
hirsutism, acne, androgenic alopecia, virilization, presence of cushingoid features. Menstrual 
cycles shorter than 25 and longer than 34 days were considered abnormal. Hirsutism was 
defined by a Ferriman-Gallwey score ≥ 8 [12], presence of acne and alopecia was recorded 
but not scored.   
Biochemical measurements 
Laboratory tests consisted of serum total testosterone (TT), dehydroepiandrostrone sulphate  
(DHEA-S), androstendione, 17OHP, sex hormone binding globulin (SHBG), albumin, TSH, 
free T4, prolactin, glucose and insulin measurements. Biochemical hyperandrogenism was 
defined as serum total testosterone, DHEA-S or androstendione above upper range of normal 
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values obtained by immunoassays. In case of clinical or biochemical suspicion of Cushing’s 
syndrome, NCCAH or CAH further diagnostic procedures were undertaken. The decisions 
about further diagnosis were based on results obtained by immunoassays.   
Cushing’s syndrome was diagnosed according to Endocrine Society guidelines [13].     
In case of basal serum 17OHP > 5.1-30 nmol/l according to Escobar-Morreale et al. [14] 
ACTH stimulation test (17OHP measurement 30’ and 60’ post ACTH im. injection) or urine 
steroid profile was performed. When basal or post-stimulated 17OHP ≥ 30 nmol/l CYP21A2 
genetic analysis and/or urine steroid profile was performed [6].   
The blood samples for hormonal assessment were collected in the morning (7.00-9.00 am) 
during the early follicular phase of the menstrual cycle (3
th
-5
th
 day).   
Assessment of TT, DHEA-S, SHBG and albumin concentrations in patients group was 
performed using ECLIA Cobas
®
 diagnostic kits (Roche Diagnostics GmbH, Mannheim, 
Germany). 17OHP measurements were performed using ELISA NovaTec
®
 (NovaTec 
Immunodiagnostica GmbH, Dietzenbach, Germany), androstendione using ELISA DRG
®
 
(DRG Instruments GmbH, Marburg, Germany) kits in the commercial laboratory. 
Independently, individuals from the studied groups had assessed serum TT, androstendione, 
17OHP levels by the ELISA DRG
®
 (DRG Instruments GmbH, Marburg, Germany) and 
DHEA-S by ECLIA Elecsys
®
 (Roche Diagnostics GmbH, Mannheim, Germany) kits assessed 
according to the manufacturer’s protocol. In all immunoassays intra- and interassay variability 
did not exceed 10 %.          
Free testosterone was calculated with the use of the formula available at 
http://www.issam.ch/freetesto.htm. 
TT, DHEA-S, androstendione and 17OHP were also assessed by LC-MS/MS in both groups.   
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LC-MS/MS measurements were performed in the Mass Spectrometry Laboratory of the 
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, samples were 
analyzed using AbsoluteIDQ Stero17 Kit produced by Biocrates Life Sciences AG 
(Innsbruck, Austria) according to the protocol supplied by the manufacturer. The intra- and 
interassay variability did not exceed 11.5%.  
TSH, free T4, prolactin and cortisol were measured using ECLIA Cobas
®
 diagnostic kits 
(Roche Diagnostics Limited, Burgess Hill, UK).   
Urine steroid profile was performed by capillary gas chromatography/mass spectrometry in 
selective ion monitoring mode (GC/MS-SIM) in the Department of Biochemistry, 
Radioimmunology and Experimental Medicine, Children’s Memorial Health Institute, 
Warsaw, Poland [15]. 
Genetic testing was performed commercially in Genomed Health Care Center (Warsaw, 
Poland). Total genomic DNA was isolated from peripheral blood leukocytes according to  
Miller et al.[16]. The CYP21A2 gene was analyzed by direct sequencing.  
 
Differential diagnosis  
Polycystic ovary syndrome was defined according to Rotterdam criteria [17].  
NCCAH/CAH was diagnosed in patients with clinical hyperandrogenism and basal and/or 
post stimulated 17OHP ≥ 30 nmol/l when confirmed by CYP21A2 genetic analysis and/or 
urine steroid profile [6].    
Idiopathic hyperandrogenism was diagnosed in case of presence of clinical and biochemical 
hyperandrogenism, regular menses and normal ovaries on ultrasound [18].     
Page 8 of 26
URL: http://mc.manuscriptcentral.com/dgye  Email: gynendo@tiscali.it
Gynecological Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
The project has been approved by the Bioethical Committee of the Medical University of 
Warsaw, and a written informed consent for participation in this study was obtained from all 
participants. The basic clinical characteristics of the studied individuals as well as of the 
control group are summarized in Table I. 
 
Statistical analysis  
The differences in 17OHP and androgens concentrations were assessed with Statistica 
software package v.10 (StatSoft, Tulsa, OK), using the Student’s t/Mann-Whitney U test. All 
correlations between quantitative values were performed with the Spearman correlation test. 
To compare the number of the individuals with the results of 17OHP > 5.1 nmol/l obtained 
with the different methods a Chi-square test with a 2x2 or 3x2 contingency tables was used. 
For all tests, the level of significance was established at 0.05. 
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Results 
Comparison of the different diagnostic methods in the assessment of serum 17- 
hydroxyprogesterone and androgens concentrations. 
 
17- hydroxyprogesterone 
The results of serum 17OHP concentrations measured by the three different diagnostic 
methods are summarized in Table II. 17OHP levels obtained by both immunoassays were 
significantly higher than by LC-MS/MS (P<0.0001). There was also significant difference 
between 17OHP level assessed by ELISA NovaTec
®
  vs  ELISA DRG
® 
(P=0.006) (Figure 1). 
Even though there was a positive correlation between the measurements obtained by ELISA 
NovaTec
® 
and by LC-MS/MS (r=0.98, P<0.0001), ELISA DRG
® 
and
 
LC-MS/MS (r=0.99, 
P<0.0001) and ELISA NovaTec
®
 and ELISA DRG
®
 (r=0.98, P<0.0001). The use of the 
different methods was associated with a different probability of obtainment of 17OHP results 
requiring further diagnosis towards NCCAH. 20 out of 36 of the patients (55.5%) had 
elevated 17OHP levels when measured by ELISA NovaTec
®
. When ELISA DRG
® 
kit was 
used 6 out of 31 (19.4%) had 17OHP concentrations above 5.1 nmol/l but measured by LC-
MS/MS only 3 out of 38 (7.9%) individuals. There was a significant difference in the 
percentage of the patients with elevated 17OHP measured by ELISA NovaTec
® 
comparing to 
LC-MS/MS as well as ELISA DRG
® 
vs
 
LC-MS/MS and ELISA NovaTec
®
 vs ELISA DRG
®
 
(P<0.0001). 
In the control group the median concentration of 17OHP assessed by ELISA DRG
® 
was 
significantly higher compared to that obtained by LC-MS/MS (P<0.0001). There was 
significant difference in median 17OHP concentration between patients and controls when 
assessed either by ELISA DRG
®
 or LC-MS/MS (P=0.0009 and P=0.0026 respectively) 
(Figure 1). 
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In the control group when ELISA DRG
® 
was used
 
1 patient out of 29 (4.4%) had 17OHP level 
elevated. None of the healthy individuals had 17OHP > 5.1 nmol/l measured by LC-MS/MS. 
Measurement of 17OHP concentrations by ELISA NovaTec
®
 was not performed in the 
control group.  
 
Androgens (total testosterone, androstendione, DHEA-S)  
The results of serum androgens concentrations measurements by the immunoassays and LC-
MS/MS are summarized in Table II.  
 
Evaluation of patients with elevated 17OHP serum level/final diagnosis  
The decision towards further diagnostics were undertaken based on the results obtained from 
ELISA NovaTec
®
 test. In all cases, however, when 17OHP was > 5.1 nmol/l in ELISA DRG
®
 
it was also elevated in ELISA NovaTec
®
 and when was elevated in LC-MS/MS it was also 
elevated in both immunoassays. 
In all, but one patient in case of basal 17OHP level 5.1-30 nmol/l further diagnostics has been 
done. One patient presented with clinical picture of Cushing’s syndrome and finally was 
diagnosed with adrenal cortical carcinoma (ACC). ACTH stimulation test was performed in 
14 patients, urine steroid profile in 7 and genetic testing in 3. 17OHP exceeded 30 nmol/l post 
ACTH stimulation in 2 patients, but further evaluation didn’t confirm NCCAH. Urine steroid 
profile was positive in 2 patients with the diagnosis of NCCAH and CAH. Genetic testing 
towards CYP21A2 mutations was negative in all 3 cases in whom was performed.           
Final diagnosis revealed in 24 (61.5%) of the patients polycystic ovary syndrome (PCOS),12 
(31%) idiopathic hyperandrogenism, 2 (5%) patients were diagnosed with CAH (1 with 
classic and 1 with nonclassic form based on urine steroid profile) and 1 (2.5%) with ACC.  
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Characteristic of the immunoassays and LC-MS/MS based on 17OHP serum 
measurements  
ELISA NovaTec
®
   
Sensitivity 100%, specificity 50%, false positive results 50%, false negative results 0%,  
positive predictive value 15%, negative predictive value 100%, test accuracy 54%. 
ELISA DRG
® 
Sensitivity 100%, specificity 92.98%, false positive results 7%, false negative results 0%,  
positive predictive value 42.86%, negative predictive value 100%, test accuracy 93.33%. 
LC-MS/MS 
Sensitivity 100%, specificity 100%, false positive results 0%, false negative results 0%,  
positive predictive value 100%, negative predictive value 100%, test accuracy 100%. 
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Discussion 
Our study showed excellent accuracy of LC-MS/MS method in 17OHP measurement 
compared to immunoassays in screening for 21-hydroxylase-deficient nonclassic adrenal 
hyperplasia in woman with hyperandrogenism.  
In the study 17OHP levels measured by LC-MS/MS were significantly lower in patients and 
in the control group compared to both immunoassays and confirm the results obtained by 
Fanelli et al. and Koal et al. [19,20]. Our results showed also that use of immunoassays is 
associated with a higher probability of false-positive results in women with hyperandrogenism 
especially when measured by ELISA NovaTec
®
 kit. Common use of immunoassays may 
therefore introduce further unnecessary diagnostic procedures, needless hospitalizations, 
additional stress for the patients and finally – lead to the false diagnosis. Our results indicate 
however that negative 17OHP level obtained by validated immunoassays speaks against 
NCCAH. Unnecessary and costly diagnostic procedures were undertaken in 17/20 (85%) 
patients when the NovaTec
®
 test was used and in 3/6 (50%) when ELISA DRG
®
 and in none 
when LC-MS/MS method was applied. Results of this study are consistent with previous 
reports regarding the comparison of immunoassays and LC-MS/MS for 17OHP 
measurements in screening for CAH during the neonatal period [6, 21, 22, 23]. However one 
should remember that the proposed basal 17OHP cut off level speaking for or against 
NCCAH was established based on immunoassays [9,14]. 17OHP cut off level by LC-MS/MS 
remains to be established, otherwise use of this method may lead to the underdiagnose of 
NCCAH, although it was not seen in case of our patients.   
According to the literature, major benefits of LC-MS/MS, apart from the high sensitivity and 
specificity, include also small sample size required for an assay, short term of sample 
preparation and possibility of measurement of multiple steroids simultaneously [20,24,25]. 
The only disadvantage is limited access to this method as well as the cost of a single 
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parameter. In our study, apart from the 17OHP measurements, we also compared 
immunoassays with LC-MS/MS results in the assessment of androgens concentrations.  
In the patients group as well as in the controls we have observed significantly lower levels of 
total testosterone, androstendione and DHEA-S when measured by LC-MS/MS compared to 
immunoassays. Similar discrepancies between HPLC-MS/MS and immunoassay based 
analysis for androstenedione were obtained by Fanelli et al. confirming the limitation of tested 
immunoassays due to the lack of immunoassay specificity by cross-reactivities with matrix 
components resulting in overestimation of the measurements [19]. These findings support  
previous studies showing that LC-MS/MS is characterized by a good precision and high 
accuracy in the measurement of androgens in women, compared with the immunoassays 
[20,26,27]. 
Our results support the data of other investigators that in measurement of steroids, especially 
for high quality clinical research, LC-MS/MS – based assays are the method of choice, so 
introduction of this method to commercial laboratories is probably a question of time [28]. 
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Table I. Clinical characteristics of the studied groups. 
 Patients with HA 
(N=39) 
Controls                        
(N=29) 
P value 
Age, mean (years, min-max) 25.9 (18-45) 27.9 (19-45)  0.52 
BMI, mean (min-max) 25.5 (17.7-47.6) 23.3 (18.6-46.8) 0.36 
Waist circumference, mean (cm, min-max) 78.5 (61-112) 76.2 (63-113) 0.80 
% of adipose tissue* mean, (min-max) 32.9 (21.2-50) 29.1 (15.8-41.6) 0.11 
Ferriman-Gallwey score, mean (min-max)  5.28 (0-18) 0.59 (0-7)  <0.0001          
Acne, n (%) 25 (64.1) 0 <0.0001 
Alopecia, n (%) 7 (17.9) 0 <0.0001 
Menstrual disturbances, n (%) 27 (69.2) 0 <0.0001 
Insulin resistance, n (%)** 
Diagnosis of PCOS, n (%) 
Diagnosis of IHA, n (%) 
Diagnosis of CAH, n (%) 
Diagnosis of ACC, n (%) 
10 (25.6) 
24 (61,5) 
12 (31)  
2 (5) 
1 (2.5) 
1 (3.3) 
- 
- 
- 
-                 
0.013 
 
HA – hyperandrogenism                                
PCOS – polycystic ovary syndrome  
IHA – idiopathic hyperandrogenism  
CAH – congenital adrenal hyperplasia 
ACC – adrenal cortical carcinoma   
n – number   
*measured by the bioelectrical impedance method  
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**definied as HOMA index value ≥ 3.0 
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Table II. Comparison of 17OHP [nmol/l], TT [nmol/l], androstendione [nmol/l] and DHEA-S [µmol/l] concentrations assessed by different 
methods in women with hyperandrogenism and in control group. 
 Patients with HA 
(median, min-max) 
Controls  
(median, min-max) 
P value 
(HA vs controls) 
 
17OHP ELISA NovaTec
® 
[N: < 5.1] 
 
5.49  (2.31-2046)
* 
 
ND 
 
 
 
17OHP ELISA DRG
® 
[N: < 5.1] 
 
3.57  (1.11-639)
 **
 
 
2.58  (0.63-2.73) 
 
0.0009 
 
17OHP LC-MS/MS 
[N: < 5.1] 
 
1.56  (0.45-756)
 ***
 
 
1.14 (1.08-4.56)
 ****
 
 
0.0026 
 
TT ECLIA Cobas
®
 
[N: 0.29-1.67] 
 
1.71  (0.8-44.16)
#
 
 
ND 
 
 
TT ELISA DRG
® 
[N: < 1.7] 
 
1.8 (0.84-79.8)
 ##
 
 
1.29  (0.31-2.30) 
 
0.0006 
 
TT LC-MS/MS 
[N: 0.1-1.6] 
 
1.28 (0.67-45.73)
 ###
 
 
0.91 (0.44-1.45)
 ####
 
 
0.0004 
 
fT ECLIA Cobas
®
 
 
 
0.023 (0.01-2.76)• 
 
ND 
 
 
fT ELISA DRG
® 
 
 
0.025 (0.009-3.11)•• 
 
ND 
 
 
fT LC-MS/MS 
 
 
0.018 (0.008-1.43) ••• 
 
ND 
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androstendione ELISA DRG
® 
commercial laboratory 
[N: 2.62-13.58] 
 
16.05 (5.86-147.6)
∆
 
 
ND 
 
 
androstendione ELISA DRG
® 
[N: < 13.58] 
 
15.18 (0.76-122.64)
 ∆ ∆
 
 
12.73 (4.05-28.02) 
 
0.202 
 
androstendione LC-MS/MS 
[N: 1.22 -8.72] 
 
6.49 (3.14-124.59)
 ∆ ∆ ∆
 
 
4.64 (0.44-2.91)
 ∆ ∆ ∆ ∆
 
 
0.002 
 
DHEA-S ECLIA Cobas
®
 
[N: 4.03-11.07 age 20-24 
       2.68-9.25  age 25-34  
       1.66-9.17  age 35-44]  
 
9.13 (2.92-27.2)
§
 
 
ND 
 
 
DHEA-S ECLIA Elecsys
® 
 [N: 4.03-11.07  age 20-24 
       2.68-9.25    age 25-34  
       1.66-9.17    age 35-44] 
 
9.43 (4.52-16.64)
 §§
 
 
7.75 (1.89-16.72) 
 
0.228 
 
DHEA-S LC-MS/MS 
[N: 1.09-8.70  age 18-29 
      1.09-8.84  age 30-49]           
 
7.45 (1.39-122.36)
 §§§
 
 
6.68 (1.32-13.95)
 §§§§
 
 
0.193 
 
HA – hyperandrogenism  
N – normal values range 
ND – not done  
LC-MS/MS – liquid chromatography coupled with mass spectrometry 
fT – free testosterone  
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*        
Patients with HA: 17OHP ELISA NovaTec
®
 vs 17OHP ELISA DRG
®
 P=0.006  
**
    Patients with HA: 17OHP ELISA NovaTec
®
 vs 17OHP LC-MS/MS P<0.0001
 
 
***
  Patients with HA: 17OHP ELISA DRG
®
 vs 17OHP LC-MS/MS P<0.0001
 
****
 Controls: 17OHP ELISA DRG
®
 vs 17OHP LC-MS/MS P<0.0001
 
 
#
     Patients with HA: TT ECLIA Cobas
®
 vs TT ELISA DRG
®
 P=0.593
 
##
    Patients with HA: TT ECLIA Cobas
®
 vs TT LC-MS/MS P=0.013
 
###
  Patients with HA: TT ELISA DRG
®
 vs TT LC-MS/MS P=0.009
 
####
 Controls: TT ELISA DRG
®
 vs TT LC-MS/MS P=0.002
 
 
•
  Patients with HA: fT ECLIA Cobas
®
 vs fT ELISA DRG
®
 P=0.806
 
••
 Patients with HA: fT ECLIA Cobas
®
 vs fT LC- MS/MS P=0.007
 
•••
  Patients with HA: TT ELISA DRG
®
 vs fT LC-MS/MS P=0.02
 
 
∆            
Patients with HA: androstendione commercial ELISA D G
®
 vs androstendione ELISA DRG
®
 P=0.69
 
∆ ∆        
Patients with HA: androstendione commercial ELISA DRG
®
 vs androstendione LC-MS/MS P<0.0001
 
∆ ∆ ∆    
Patients with HA: androstendione ELISA DRG
®
 vs androstendione LC-MS/MS P<0.0001
 
∆ ∆ ∆ ∆
 Controls: androstendione ELISA DRG
®
 vs androstendione LC-MS/MS P<0.00001 
 
§
        Patients with HA: DHEA-S ECLIA Cobas
®
 vs DHEA-S RIA Elecsys
®
 P=0.973
 
§§         
Patients with HA: DHEA-S ECLIA Cobas
®
 vs DHEA-S LC-MS/MS P=0.006 
§§§
     Patients with HA: DHEA-S ECLIA Elecsys
 ®
 vs DHEA-S LC-MS/MS P=0.02 
§§§§
   Controls: DHEA-S ECLIA Elecsys
 ®
 vs DHEA-S LC-MS/MS P=0.03 
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Figure 1. Comparison of  the 17OHP levels  assessed by the different methods in the studied 
group of women with hyperandrogenism (HA) and in the control group. 
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